News: CVS Health Corp (CVS.N)

CVS.N on New York Stock Exchange

100.39USD
17 Apr 2015
Change (% chg)

$-0.78 (-0.77%)
Prev Close
$101.17
Open
$100.59
Day's High
$100.72
Day's Low
$99.25
Volume
1,720,355
Avg. Vol
1,356,039
52-wk High
$105.45
52-wk Low
$72.45

Search Stocks
Select another date:

Wed, Mar 11 2015

Photo

Exclusive: CVS says biotech drug copies may bring price cuts of 40-50 percent

WASHINGTON - The entry of copycat biotech drugs into the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, depending on the level of competition among drugmakers, a top executive at CVS Health Corp told Reuters.

UPDATE 1-Samsung buys startup LoopPay, moves toward mobile payments

Feb 18 - Samsung Electronics Co Ltd has bought U.S. mobile wallet startup LoopPay, signalling its intention to launch a smartphone payments service to compete with a recent offering from rival Apple Inc.

CVS urges cost controls for new cholesterol drugs

- CVS Health warned on Tuesday that the costs of a potent new class of cholesterol treatments could eclipse those of other expensive medicines and overwhelm the U.S. healthcare system "if rigid cost control mechanisms are not put in place."

UPDATE 2-CVS urges cost controls for new cholesterol drugs

Feb 17 - CVS Health warned on Tuesday that the costs of a potent new class of cholesterol treatments could eclipse those of other expensive medicines and overwhelm the U.S. healthcare system "if rigid cost control mechanisms are not put in place."

CORRECTED-UPDATE 1-CVS urges cost controls for new cholesterol, specialty drugs

Feb 17 - CVS Health on Tuesday warned that costs of a potent new class of cholesterol treatments and other specialty drugs in development could eclipse those of expensive new medicines and overwhelm the healthcare system "if rigid cost control mechanisms are not put in place."

CVS says new cholesterol drugs could cost U.S. $150 bln/year

Feb 17 - CVS Health Corp, the second-largest U.S. pharmacy chain operator, has warned that a new class of drugs being developed to lower "bad" cholesterol could cost the U.S. healthcare system as much as $150 billion per year.

CVS Health revenue beats as pharmacy services sales rise

- CVS Health Corp reported a better-than-expected quarterly net revenue, boosted by growth in its Medicaid business and strength in specialty drug sales.

UPDATE 2-CVS Health revenue beats as pharmacy services sales rise

Feb 10 - CVS Health Corp reported a better-than-expected quarterly net revenue, boosted by growth in its Medicaid business and strength in specialty drug sales.

CVS Health revenue rises nearly 13 pct

Feb 10 - CVS Health Corp, the No. 2 U.S. drugstore operator, reported a near 13 percent rise in quarterly net revenue, helped by an increase in pharmacy same-store sales.

AbbVie expects more than $3 billion in annual hepatitis C drug sales

- AbbVie Inc's chief executive said on Friday the company's new hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences .

Select another date:
Search Stocks